USPTO Examiner SCHNIZER RICHARD A - Art Unit 1635

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18799447MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYAugust 2024December 2024Allow410NoNo
18416981MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYJanuary 2024June 2024Allow510NoNo
18504029INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUIDNovember 2023April 2024Abandon501YesNo
17736148EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHYMay 2022February 2023Allow910NoNo
17571193RNAi Insecticide Materials and MethodsJanuary 2022February 2025Allow3700NoNo
17554274NXTAR-DERIVED OLIGONUCLEOTIDES AND USES THEREOFDecember 2021August 2024Allow3221YesNo
17527953MODULATORS OF YAP1 EXPRESSIONNovember 2021April 2025Abandon4110NoNo
17520530Methods and Compositions for Selecting siRNA of Improved FunctionalityNovember 2021April 2025Abandon4101NoNo
17387495NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDESJuly 2021January 2025Allow4210NoNo
17384417Stabilized CRISPR ComplexesJuly 2021May 2024Allow3410YesNo
17380756TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICSJuly 2021September 2024Abandon3810NoNo
17422118GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED TRANSFERRIN GENEJuly 2021May 2025Abandon4721NoNo
17367242TAU ANTISENSE OLIGOMERS AND USES THEREOFJuly 2021May 2025Abandon4610NoNo
17364618ANTISENSE NUCLEIC ACIDSJune 2021August 2024Allow3810NoNo
17416735DNA APTAMERS SPECIFIC OF ADENOVIRUS TYPESJune 2021February 2025Allow4410NoNo
17352716BENZIMIDAZOLES THAT ENHANCE THE ACTIVITY OF OLIGONUCLEOTIDESJune 2021March 2025Abandon4410NoNo
17413550DNA APTAMERS AND USE THEREOF FOR THE TREATMENT OF CANCERJune 2021May 2024Allow3510YesNo
17345624EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHYJune 2021June 2024Abandon3710NoNo
17245735EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHYApril 2021December 2021Allow710NoNo
17244272ANTIVIRAL AGENTS FOR TREATMENT OF CORONAVIRUSESApril 2021June 2024Allow3720YesNo
17238612USING MICRORNAS TO CONTROL ACTIVATION STATUS OF HEPATIC STELLATE CELLS AND TO PREVENT FIBROSIS IN PROGRESSIVE LIVER DISEASESApril 2021April 2025Allow4820NoNo
17236851MICRORNA-198 AS A TUMOR SUPPRESSOR IN OVARIAN CANCERApril 2021June 2024Allow3810NoNo
17205102MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYMarch 2021January 2024Allow3440YesYes
17200146GFI1 INHIBITORS FOR THE TREATMENT OF HYPERGLYCEMIAMarch 2021May 2024Abandon3801NoNo
17178846Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using SameFebruary 2021June 2024Abandon4010NoNo
17177111OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOFFebruary 2021April 2025Allow5001NoNo
17168709TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENTFebruary 2021April 2025Abandon5030NoNo
17266556COMPOSITIONS AND AGENTS AGAINST NONALCOHOLIC STEATOHEPATITISFebruary 2021April 2025Abandon5020NoNo
17159586Use of Trinucleotide Repeat RNAs To Treat CancerJanuary 2021December 2024Allow4711YesNo
17131130RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular DystrophyDecember 2020October 2024Abandon4511NoNo
17108450ANTI-ARID3A TREATMENTS FOR INFLAMMATORY DISORDERSDecember 2020May 2025Abandon5420NoNo
17106259LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2020May 2024Abandon4101NoNo
17056233Drug-Resistant Immune Cells and Methods of Use ThereofNovember 2020February 2025Allow5121NoNo
17053713Applications of Streptococcus-derived Cas9 nucleases on minimal Adenine-rich PAM targetsNovember 2020November 2024Abandon4811NoNo
17048227SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNAOctober 2020February 2025Allow5211NoNo
17047271NOVEL SUBSTITUTED RIG-I AGONISTS: COMPOSITIONS AND METHODS THEREOFOctober 2020August 2022Allow2220NoNo
17033313SEQUENCE-SPECIFIC IN VIVO CELL TARGETINGSeptember 2020March 2022Allow1721YesNo
16947905INHIBITION OF MIR-22 MIRNA BY APT-110August 2020January 2025Allow5320NoNo
16999506Direct and Selective Inhibition of MDM4 for Treatment of CancerAugust 2020June 2024Allow4620NoNo
16999695ANTISENSE NUCLEIC ACIDSAugust 2020August 2024Allow4811NoNo
16999051Methods and Compositions for Preventing or Treating Heart DiseaseAugust 2020May 2025Abandon5721NoNo
16987050Read Through Of Truncated Proteins In Premature Termination Codon Diseases Using An Optimized Genetic Codon Expansion SystemAugust 2020October 2022Allow2721YesNo
16984887COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSIONAugust 2020December 2021Allow1600NoNo
16936060MODULATORS OF PNPLA3 EXPRESSIONJuly 2020May 2023Allow3420YesNo
16927452NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOFJuly 2020June 2022Abandon2320NoNo
16957249PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING PULMONARY METASTASIS OF CANCER INCLUDING CHI3L1 INHIBITOR AS ACTIVE INGREDIENTJune 2020July 2022Allow2510NoNo
16956827DNA ORIGAMI NANOPARTICLE DELIVERY OF PROGRAMMED CHROMOSOME BREAKAGE MACHINERYJune 2020September 2024Abandon5131NoNo
15733307OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGEJune 2020May 2024Abandon4740NoNo
16884782MODULATORS OF GROWTH HORMONE RECEPTORMay 2020June 2022Abandon2401NoNo
16872051MODIFICATIONS OF MAMMALIAN CELLS USING ARTIFICIAL MICRO-RNA TO ALTER THEIR PROPERTIES AND THE COMPOSITIONS OF THEIR PRODUCTSMay 2020June 2021Allow1421NoNo
16867925COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPAMay 2020September 2024Abandon5341YesNo
16851689COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTIONApril 2020October 2022Abandon3020NoYes
16847499PREECLAMPSIAApril 2020February 2023Allow3421YesNo
16812714BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERYMarch 2020April 2024Allow5131NoYes
16811476LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFMarch 2020January 2021Abandon1010NoNo
16645083COMPOSITIONS AND METHODS FOR TREATING TRANSPOSON ASSOCIATED DISEASESMarch 2020January 2024Allow4731YesNo
16806941COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSIONMarch 2020January 2022Abandon2230NoNo
16802014NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNAFebruary 2020February 2022Allow2410NoNo
16782976Methods and Compositions for Selecting siRNA of Improved FunctionalityFebruary 2020August 2021Allow1811NoNo
16778949MODULATORS OF YAP1 EXPRESSIONJanuary 2020August 2021Allow1910NoNo
16777214THERAPEUTIC SPLICE-SWITCHING OLIGONUCLEOTIDESJanuary 2020April 2022Allow2750YesNo
16774910ANTICANCER THERAPEUTIC INTERVENTIONJanuary 2020December 2021Allow2331YesNo
16631995NUCLEIC ACID SIMULTANEOUSLY INHIBITING EXPRESSION OF AR GENE AND MTOR GENEJanuary 2020November 2020Allow1010YesNo
16628811METHODS FOR TREATING INFLAMMATION AND RELATED DISEASES AND DISORDERS BY INHIBITING ALPHA PROTEIN KINASE 1January 2020September 2024Abandon5651NoNo
16732740METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE ENDURANCE, PERFORMANCE, OR TOLERANCEJanuary 2020June 2021Abandon1850YesNo
16501000FUNCTION INHIBITOR OF SWI/SNF COMPLEXESDecember 2019January 2022Abandon2701NoNo
16716705LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFDecember 2019December 2020Abandon1210NoNo
16710144EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPYDecember 2019June 2021Abandon1820NoNo
16617631TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDESNovember 2019November 2024Abandon6042NoNo
16617743NUCLEIC ACID SUPPRESSING EXPRESSION OF APCSNovember 2019May 2022Allow3011YesNo
16617431THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE IIINovember 2019April 2022Allow2901YesNo
16614644COMPOSITION FOR PREVENTION OR TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 36November 2019August 2021Allow2130NoNo
16680340siRNA Targeting LDHANovember 2019October 2020Abandon1110NoNo
16678600NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOFNovember 2019April 2020Allow510YesNo
16612313NEW THERAPYNovember 2019June 2023Allow4330NoNo
16611046MODULATORY POLYNUCLEOTIDESNovember 2019January 2022Abandon2610NoNo
16664527Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)October 2019October 2022Abandon3601NoNo
16660986TREATMENT STRATEGIES AGAINST ANTHRAX BY INTERFERING WITH CRITICAL HOST FACTORSOctober 2019November 2023Allow4981YesNo
16606236METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTIONOctober 2019May 2022Allow3120YesNo
16596553METHOD OF MANUFACTURING VESICLES BY DELIVERY OF RNA NANOPARTICLES AND VESICLES MANUFACTURED USING THE SAMEOctober 2019January 2024Abandon5240YesNo
16498408REGULATION OF MIR-143 USING NUCLEIC ACID MOLECULESSeptember 2019August 2023Allow4661YesYes
16496720VECTORS AND COMPOSITIONS FOR TREATING HEMOGLOBINOPATHIESSeptember 2019October 2021Allow2540YesNo
16496761GFI1 INHIBITORS FOR THE TREATMENT OF HYPERGLYCEMIASeptember 2019December 2020Allow1520NoNo
16495555METHOD FOR PREDICTION OF SUSCEPTIBILITY TO SORAFENIB TREATMENT BY USING SULF2 GENE, AND COMPOSITION FOR TREATMENT OF CANCER COMPRISING SULF2 INHIBITORSeptember 2019July 2022Allow3431YesNo
16574407MODULATORS OF PNPLA3 EXPRESSIONSeptember 2019May 2020Allow800NoNo
16572234HORNERIN: A NOVEL NON-VEGF MEDIATED ANGIOGENIC PROTEIN EXPRESSED IN BOTH HUMAN AND MOUSE ANGIOGENIC ENDOTHELIAL CELLS AND HUMAN PANCREATIC CANCER CELLSSeptember 2019March 2024Allow5431NoNo
16559568TREATMENT OF ALZHEIMERS DISEASE WITH MICRO RNA AND GHRELINSeptember 2019July 2023Abandon4630YesNo
16554115Compositions for Modulating Expression of C9ORF72 Antisense TranscriptAugust 2019August 2021Allow2420NoNo
16551847RNAI STRATEGIES FOR CONTROL OF WHITEFLYAugust 2019April 2021Allow2021YesNo
16487587REGULATION OF GENE EXPRESSION BY APTAMER-MODULATED RNASE P CLEAVAGEAugust 2019April 2023Allow4420NoNo
16487223Regulation of Gene Expression by Aptamer-Mediated Accessibility of Polyadenylation SignalsAugust 2019May 2023Abandon4520NoNo
16487377SYSTEM AND METHOD FOR CELL TYPE-SPECIFIC TRANSLATION OF RNA MOLECULES IN EUKARYOTESAugust 2019April 2024Allow5631YesNo
16540973METHODS AND COMPOSITIONS FOR TREATING MALIGNANT TUMORS ASSOCIATED WITH KRAS MUTATIONAugust 2019October 2021Allow2621YesNo
16530600Molecular Recognition Systems with Pyrimidine Analog PairingAugust 2019July 2020Allow1110NoNo
16483012POLYNUCLEOTIDE SECONDARY STRUCTUREAugust 2019January 2023Abandon4131NoYes
16521344COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSIONJuly 2019April 2020Allow910NoNo
16477656ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSIONJuly 2019February 2021Abandon1911NoNo
16475275NUCLEIC ACIDS AND METHODS FOR GENOME EDITINGJuly 2019February 2024Abandon5510NoNo
16474776ENDOSOMAL CLEAVABLE LINKERSJune 2019November 2021Allow2821YesNo
16449093COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDSJune 2019January 2022Allow3130YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHNIZER, RICHARD A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
8
Examiner Affirmed
6
(75.0%)
Examiner Reversed
2
(25.0%)
Reversal Percentile
37.7%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
123
Allowed After Appeal Filing
17
(13.8%)
Not Allowed After Appeal Filing
106
(86.2%)
Filing Benefit Percentile
16.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SCHNIZER, RICHARD A - Prosecution Strategy Guide

Executive Summary

Examiner SCHNIZER, RICHARD A works in Art Unit 1635 and has examined 896 patent applications in our dataset. With an allowance rate of 45.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner SCHNIZER, RICHARD A's allowance rate of 45.4% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SCHNIZER, RICHARD A receive 2.20 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SCHNIZER, RICHARD A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +36.3% benefit to allowance rate for applications examined by SCHNIZER, RICHARD A. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.5% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.4% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.2% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 87.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 12.6% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.9% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.